Resources|Articles|November 8, 2024
Adopting novel technologies to improve monoclonal antibody processes
Author(s)Avantor
The growing complexity of therapeutic monoclonal antibodies (mAbs), especially bispecific antibodies, presents significant manufacturing challenges such as instability, low yields and aggregation. This article explores innovative solutions, including detergent-based viral inactivation as an alternative to low pH treatment, high- performance chromatography ligands and advanced formulation excipients.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Trending on Pharmaceutical Technology
1
Drug Digest: Strategic Alliances and Technology Integration in the Evolving Biopharma Landscape
2
Clearing Hurdles in Sustainability, AI, and CDMO Partnerships
3
Excipient Innovation and the Regulatory Tug-of-War: Navigating Threats to Availability and Safety
4
US and European Pharma Manufacturing Face Diverging Paths to Resilience
5
